Cargando…

Adalimumab for severe psoriasis in Chilean paediatric patients()()

Detalles Bibliográficos
Autores principales:	Armijo Fernandez, Daniela, Valenzuela, Fernando, Saint-Pierre Contreras, Gustavo, Cortés González, Andrea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sociedade Brasileira de Dermatologia 2020
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7058876/ https://www.ncbi.nlm.nih.gov/pubmed/31959513 http://dx.doi.org/10.1016/j.abd.2019.04.012

Ejemplares similares

Comorbidities in Chilean patients with psoriasis: a Global Healthcare Study on Psoriasis
por: Valenzuela, Fernando, et al.
Publicado: (2022)

Secukinumab: Rapid Efficacy in Psoriasis After Primary Failure With Ustekinumab and Adalimumab
por: Okita, Aline Lissa, et al.
Publicado: (2020)

Treating psoriasis with adalimumab
por: Alwawi, Eihab A, et al.
Publicado: (2008)

Drug focus: adalimumab in the treatment of moderate to severe psoriasis
por: Vena, Gino A, et al.
Publicado: (2007)

Adalimumab in Recalcitrant Severe Psoriasis Associated with Atopic Dermatitis
por: Yayli, Savas, et al.
Publicado: (2013)

Surveillance of seasonal respiratory viruses among Chilean patients during the COVID‐19 pandemic
por: Alonso‐Palomares, Luis A., et al.
Publicado: (2021)

Sarcoid-like granulomatous reaction in the lung mimicking miliary tuberculosis in a patient receiving adalimumab for psoriasis
por: AKDOĞAN, Neslihan, et al.
Publicado: (2021)

Response to the Letter to the Editor: Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
por: Fitzgerald, Timothy, et al.
Publicado: (2023)

Efficacy of ixekizumab on nail psoriasis in paediatric patients with moderate‐to‐severe psoriasis: a post hoc analysis from IXORA‐PEDS
por: Seyger, M.M.B., et al.
Publicado: (2021)

BDNF and Cognitive Function in Chilean Schizophrenic Patients
por: Nieto, Rodrigo R., et al.
Publicado: (2023)

Thalamic stroke in a young adult with severe psoriasis refractory to adalimumab
por: Kadayakkara, Deepak Kana, et al.
Publicado: (2015)

COVID-19 in patients with psoriasis: A Latin American case series
por: Campo-Slebi, Isabela, et al.
Publicado: (2021)

Regaining adequate treatment responses in patients with psoriasis who discontinued dose reduction of adalimumab, etanercept or ustekinumab
por: van der Schoot, Lara S., et al.
Publicado: (2022)

Addition of Cyclosporine to Adalimumab Improved Psoriasis And Adalimumab-Induced Injection Site Reaction
por: Nakamizo, Satoshi, et al.
Publicado: (2014)

Comparative efficacy of secukinumab against adalimumab and infliximab in patients with moderate-to-severe plaque psoriasis
por: Pan, Ran, et al.
Publicado: (2022)

Successful treatment of a child’s generalized pustular psoriasis with adalimumab in combination with low-dose acitretin
por: Arasiewicz, Hubert, et al.
Publicado: (2023)

Adalimumab for endoscopic and histopathological mucosal healing in paediatric patients with moderate to severe Crohn’s disease
por: Szymanska, Edyta, et al.
Publicado: (2016)

Sustained long‐term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double‐blind, phase III study
por: Thaçi, D., et al.
Publicado: (2019)

Letter to the Editor: Response to Fitzgerald T et al. Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
por: Blauvelt, Andrew, et al.
Publicado: (2023)

Real-World Outcomes of Adalimumab Treatment for Moderate and Severe Psoriasis in Korean Patients (RAPSODI Study)
por: Kim, Dong Hyun, et al.
Publicado: (2023)

Guillain-Barré syndrome in a patient on adalimumab for the treatment of psoriasis
por: de Natividade, Natallia Barreiros, et al.
Publicado: (2017)

Arthropathic psoriasis complicated by a paradoxical reaction in the form of erythrodermic psoriasis following adalimumab and by an allergic reaction following infliximab which was successfully managed with secukinumab
por: Tichy, Martin
Publicado: (2019)

Real-World Evidence From More Than 1000 Patients Treated With Adalimumab For Moderate-to-Severe Psoriasis in the Czech Republic
por: Kojanova, Martina, et al.
Publicado: (2021)

Cellular Immune Response in Patients Immunized with Three Vaccine Doses of Different Vaccination Schemes Authorized by the Chilean Ministry of Health in January 2022
por: Tabilo Valenzuela, Paz Beatriz, et al.
Publicado: (2022)

Visual Loss Induced by Adalimumab Used for Plaque Psoriasis
por: Saffra, Norman, et al.
Publicado: (2017)

An Update Review of Biosimilars of Adalimumab in Psoriasis – Bioequivalence and Interchangeability
por: Zhou, Xin, et al.
Publicado: (2021)

Association of Trabecular Bone Score with Inflammation and Adiposity in Patients with Psoriasis: Effect of Adalimumab Therapy
por: Hernández, José L., et al.
Publicado: (2016)

MMP-9 Levels in the Gingival Crevicular Fluid of Chilean Rosacea Patients
por: Fernández, Javier, et al.
Publicado: (2022)

Outcome of adalimumab monotherapy in paediatric non-infectious uveitis
por: Al-Julandani, DA, et al.
Publicado: (2023)

Resolution of post-adalimumab vitiligo with secukinumab in a patient with psoriasis vulgaris
por: Palazzo, Giovanni
Publicado: (2020)

Rituximab-Induced Psoriasis in a Patient with Granulomatosis with Polyangitis Treated with Adalimumab
por: Alahmari, Hana S., et al.
Publicado: (2019)

The effect of biosimilar administration on clinical outcomes in patients with adalimumab‐controlled psoriasis
por: Panahi, M., et al.
Publicado: (2021)

Real-Life Effectiveness of Adalimumab Biosimilars in Patients with Chronic Plaque Psoriasis
por: Bellinato, Francesco, et al.
Publicado: (2022)

Effects of adalimumab and secukinumab on comorbidities associated with metabolism in patients with plaque psoriasis
por: Zhang, Si, et al.
Publicado: (2022)

Long-term use of adalimumab in the treatment of moderate to severe plaque psoriasis: a review of the literature
por: Moore, Angela Y, et al.
Publicado: (2010)

Treatment satisfaction, safety and effectiveness of adding methotrexate to adalimumab in patients with psoriasis responding suboptimally to adalimumab in a real‐world setting
por: Papp, K.A., et al.
Publicado: (2022)

Dermatofibrosarcoma protuberans (DFSP) with fibrosarcomatous changes in a patient with psoriasis treated with adalimumab
por: Belyaeva, Elizaveta A., et al.
Publicado: (2015)

Safety and efficacy of adalimumab treatment in Japanese patients with psoriasis: Results of SALSA study
por: Asahina, Akihiko, et al.
Publicado: (2016)

Hair whitening in a patient with psoriasis on adalimumab reversed after switching to ixekizumab
por: Raimondo, Annunziata, et al.
Publicado: (2021)

Long-Term Dose Optimization of Adalimumab via Dose Spacing in Patients with Psoriasis
por: Benzaquen, Michael, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ms0dee6b4ekohmmde420dbofer